Delavirdine
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: delavirdine mesilate, delavirdine mesylate, rescriptor
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Delavirdine is an ofm drug in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Non-Nucleoside Reverse Transcriptase Inhibitors. DrugCentral lists 8 molecular targets, including pol, pol and gag-pol. Recorded indications include Human immunodeficiency virus infection.
- Approval status: ofm (first approved 1997 by the FDA).
- Drug class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.
- Mechanism of action: Non-Nucleoside Reverse Transcriptase Inhibitors.
- Molecular targets: pol, pol, gag-pol and reverse transcriptas (8 listed in DrugCentral).
- Indications: Human immunodeficiency virus infection.
- ATC code: J05AG02 (Non-nucleoside reverse transcriptase inhibitors).
- Molecular formula: C22H28N6O3S; molecular weight 456.57 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Human immunodeficiency virus infection
Contraindications (3)
- Achlorhydria
- Breastfeeding (mother)
- Disease of liver
Mechanism & targets
| Mechanism of action (MoA) | Non-Nucleoside Reverse Transcriptase Inhibitors |
|---|---|
| Established pharmacologic class | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
Molecular targets (8)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Pol polyprotein | pol | unknown | IC50 8.89 |
| Reverse transcriptase/RNaseH | pol | inhibitor | IC50 8.10 |
| Gag-Pol polyprotein | gag-pol | unknown | IC50 6.50 |
| Reverse transcriptase | reverse transcriptas | unknown | IC50 5.92 |
| Histamine H4 receptor | HRH4 | unknown | Ki 5.28 |
| ATP-binding cassette sub-family G member 2 | ABCG2 | unknown | IC50 4.73 |
| Malate dehydrogenase cytoplasmic | MDH1 | unknown | IC50 4.07 |
| Beta-lactamase | ampC | unknown | IC50 4.05 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-04-04 | FDA | — | VIIV HLTHCARE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AG02 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Non-nucleoside reverse transcriptase inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Mitochondrial toxicity | 643.2 |
| Progressive external ophthalmoplegia | 617.0 |
| Lipodystrophy acquired | 610.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Delavirdine is on its molecule page.
| Molecular formula | C22H28N6O3S |
|---|---|
| Molecular weight | 456.57 g/mol |
| CAS number | 136817-59-9 |
| InChIKey | WHBIGIKBNXZKFE-UHFFFAOYSA-N |
| PubChem CID | 5625 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Delavirdine used for?
DrugCentral lists the following indications for Delavirdine: Human immunodeficiency virus infection.
How does Delavirdine work?
Delavirdine is classified as Non-Nucleoside Reverse Transcriptase Inhibitors; its molecular targets in DrugCentral include pol, pol (inhibitor), gag-pol and reverse transcriptas.
When was Delavirdine first approved?
Delavirdine was first approved by the FDA in 1997.
What drug class does Delavirdine belong to?
Delavirdine is in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.
What is the chemical formula of Delavirdine?
Delavirdine has the molecular formula C22H28N6O3S and a molecular weight of 456.57 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 799 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL593 — compound record and bioactivity
- PubChem CID 5625 — chemical identifiers
- DrugBank DB00705 — drug record
- FDA UNII DOL5F9JD3E — substance identity
- DailyMed: FDA labels for Delavirdine — current prescribing information (label search)
- UniProt Q9H3N8 (HRH4) — target protein
- UniProt Q9UNQ0 (ABCG2) — target protein
- UniProt P40925 (MDH1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.